Developments FDA grants GRI ODD for GRI-0621 in IPF GRI Bio (NASDAQ: GRI) has announced that the FDA has granted Orphan Drug Designation (ODD) to GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible and ultimately fatal lung... June 18, 2026